Stephanie Kubacak, MD
Internal Medicine · Odessa, TXNPI 1821086729
Payments from drug & device makers
Across 294 payments — averaging $17.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$777
- Novo Nordisk$632
- Amgen$502
- Lilly USA, LLC$461
- AbbVie$285
- Ardelyx, Inc.$234
- plus $2K from 24 others
What the payments were for
- Food & beverage$4,99998%
- Education$852%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 48 | $777 |
| Novo Nordisk | 41 | $632 |
| Amgen | 30 | $502 |
| Lilly USA, LLC | 29 | $461 |
| AbbVie(2 entities) | 16 | $285 |
| Ardelyx, Inc. | 8 | $234 |
| Boehringer Ingelheim | 11 | $230 |
| Abbott | 10 | $218 |
| Astellas Pharma US Inc | 8 | $210 |
| Merck | 15 | $178 |
| Radius Health, Inc. | 10 | $163 |
| GSK | 8 | $144 |
| Tactile Systems Technology Inc | 5 | $123 |
| Exact Sciences | 7 | $122 |
| Sumitomo Pharma America, Inc. | 4 | $96 |
| Amarin Pharma, Inc. | 6 | $91 |
| Pfizer | 5 | $75 |
| Novartis | 4 | $74 |
| Boston Scientific | 3 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $72 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Johnson & Johnson | 3 | $49 |
| Phathom Pharmaceuticals, Inc. | 2 | $48 |
| Sanofi Pasteur Inc. | 3 | $43 |
| Mylan Specialty L.p. | 2 | $42 |
| Bayer | 2 | $32 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Philips North America LLC | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$5,084 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 224 | $171,512 |
| RybelsusSemaglutide | 105 | $130,350 |
| JanuviaSitagliptin Phosphate | 106 | $121,363 |
| OzempicSemaglutide | 104 | $92,347 |
| MounjaroTirzepatide | 79 | $86,186 |
| JardianceEmpagliflozin | 89 | $82,423 |
| FarxigaDapagliflozin Propanediol | 83 | $74,107 |
| TradjentaLinagliptin | 65 | $64,539 |
| GlyxambiEmpagliflozin/Linagliptin | 85 | $59,500 |
| CreonLipase/Protease/Amylase | 22 | $51,346 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 58 | $49,545 |
| XareltoRivaroxaban | 53 | $40,269 |
| MyrbetriqMirabegron | 68 | $37,808 |
| ProliaDenosumab | 21 | $35,308 |
| TrulicityDulaglutide | 29 | $32,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $632 | $222,697209 claims |
| Boehringer IngelheimJardiance, Tradjenta, Glyxambi | $230 | $206,461239 claims |
| PfizerEliquis | $75 | $171,512224 claims |
| MerckJanuvia, Janumet | $178 | $138,823118 claims |
| Lilly USA, LLCMounjaro, Trulicity | $461 | $118,495108 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere, Symbicort | $777 | $97,629131 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $144 | $86,908145 claims |
| AbbVieCreon, Linzess, Synthroid | $285 | $82,307183 claims |
| Johnson & JohnsonXarelto | $49 | $40,26953 claims |
| Astellas Pharma US IncMyrbetriq | $210 | $37,80868 claims |
| AmgenProlia | $502 | $35,30821 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $72 | $19,50129 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Odessa
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.